WHAT IS CLAIMED IS:

1. Use of a composition in the manufacture of a medicament for treating presbyopia, wherein the composition is pharmaceutically acceptable and comprises pilocarpine hydrochloride at a concentration of 1.25% w/v, wherein pilocarpine hydrochloride is the sole active ingredient, and wherein the composition further comprises boric acid, sodium citrate dihydrate, sodium chloride, hydrochloric acid and/or sodium hydroxide, and water.

2. The use of claim 1, wherein the composition is to be applied once daily or twice daily.

3. The use of any preceding claim, wherein the composition comprises 1.25% w/v pilocarpine hydrochloride, 1.0% w/v boric acid, 0.015% w/v sodium citrate dihydrate, 0.08% w/v sodium chloride, and further comprises 0.0075% w/v benzalkonium chloride.

4. The use of any preceding claim, wherein the composition does not comprise a polymer.

5. The use of any preceding claim, wherein the composition consists essentially of 1.25% w/v pilocarpine hydrochloride, 1.0% w/v boric acid, 0.015% w/v sodium citrate dihydrate, 0.08% w/v sodium chloride, and 0.0075% w/v benzalkonium chloride, with a pH of 5.0.

6. Use of a composition in the manufacture of a medicament for improving at least one vision parameter in a patient with presbyopia, wherein the composition is pharmaceutically acceptable, and wherein the composition comprises 1.25% w/v pilocarpine hydrochloride, boric acid, sodium citrate dihydrate, sodium chloride, hydrochloric acid and/or sodium hydroxide, and water, and wherein the at least one vision parameter is selected from the group consisting of near vision acuity, distance vision acuity, night vision, day vision, glare, and light scattering, wherein pilocarpine hydrochloride is the sole active ingredient.

7. The use of claim 6, wherein the vision parameter is near vision acuity or is distance vision acuity.

8. The use of any one of claims 6-7, wherein the composition does not comprise a polymer.

9. Use of a composition in the manufacture of a medicament for improving near vision in a patient with presbyopia, the composition comprising 1.25% w/v pilocarpine hydrochloride, 1.0% w/v boric acid, 0.015% w/v sodium citrate dihydrate, 0.08% w/v sodium chloride, 0.0075% w/v benzalkonium chloride, and water, with a pH of 3.0-5.5, wherein pilocarpine hydrochloride is the sole active ingredient.

10. The use of claim 9, wherein the composition does not comprise a polymer.